Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MMP2 | P08253 | 6/20 | 0.52 |
| ▸ | MMP13 | P45452 | 2/20 | 0.52 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 5/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HPN | P05981 | 1/20 | 0.50 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20335059 | 0.90 | CTSL (0.68) | CTSLMMP2MMP13MMP3MMP9 | |
| SCHEMBL20335058 | 0.90 | CTSL (0.68) | CTSLMMP2MMP13MMP3MMP9 | |
| SCHEMBL29883707 | 0.88 | CTSL (0.54) | CTSLLMNAMMP2MMP13MMP3 | |
| SCHEMBL30689128 | 0.86 | CTSL (0.63) | CTSLMMP2MMP9CA2ALDH1A1 | |
| SCHEMBL5221010 | 0.86 | LMNA (0.55) | CTSLLMNAMMP2MMP13MMP9 | |
| SCHEMBL20335050 | 0.85 | LMNA (0.68) | CTSLLMNAMMP2MMP9CA2 | |
| SCHEMBL8623372 | 0.85 | CTSL (0.52) | CTSLLMNAMMP2MMP13MMP3 | |
| SCHEMBL20335049 | 0.85 | LMNA (0.68) | CTSLLMNAMMP2MMP9CA2 | |
| SCHEMBL30689105 | 0.85 | ALDH1A1 (0.56) | CTSLLMNAMMP2MMP13MMP3 | |
| SCHEMBL8813851 | 0.84 | CTSL (0.61) | CTSLMMP2MMP9CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SERPINC1, PLAT, F2 | CTSL 242/4885LMNA 999/4885MMP2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.